BioPharma Dive - Latest News

Novo abruptly ends obesity drug deal with Hims

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo resolved its shortage.

Jun 23, 2025 - 17:45
 0
Novo abruptly ends obesity drug deal with Hims

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo resolved its shortage.

Read More

Tags:

Previous Article

Cidara stock soars as antiviral drug succeeds in flu study

Next Article

Compass’ big psychedelic study doesn’t impress investors

Related Posts

Could the FDA take an indirect approach to regulate lab developed tests?

Could the FDA take an indirect approach to regulate lab...

Jun 16, 2025  0

A bespoke CRISPR therapy suggests a blueprint for treating ‘N-of-1’ diseases

A bespoke CRISPR therapy suggests a blueprint for treat...

May 15, 2025  0

Metsera shares climb on early data for amylin-targeting obesity shot

Metsera shares climb on early data for amylin-targeting...

Jun 9, 2025  0